Clinical Trial Update: Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union. [NA]

View source ↗

Summary

The EU Risk Management Plan survey for purchasers of Alli (60 mg orlistat) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• ALLI (orlistat)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Weight Loss | NA | Status: WITHDRAWN